Diana Acosta

Objetivo: Sales profesional extensive in the Pharmacutical industry with an evolutionary visión of at GenePlanet

Diana Acosta has extensive work experience in the pharmaceutical industry. Diana started their career as a Medical Sales Representative at Janssen-Cilag Polska Sp. z o.o. in 2002. Diana then joined MSD as a Medical Sales Representative from 2004 to 2010, where they excelled in promoting innovative and safe molecules for various medical treatments. Diana also worked at Pfizer as a Medical Sales Representative from 2010 to 2015.

In 2016, Diana joined Abbott Laboratories de México as a Medical Sales Representative, where they achieved significant sales growth for innovative molecules in the Central Nervous System line. Diana continued to excel in the pharmaceutical industry and joined Pierre Fabre Medicament Production as a Master Medical Representative from 2018 to 2019. Diana then worked at Asofarma de Mexico as a Master Medical Representative, generating sales and organizing events for specific pharmaceutical products.

Most recently, Diana worked at GenePlanet as a Product Specialist, where they demonstrated their extensive sales experience and evolutionary vision of current roles in the pharmaceutical industry. Currently, they are employed as an International Market Business Development Executive at Informa Markets, utilizing their expertise in business development and market expansion.

Throughout their career, Diana has proven to be an engaged, assertive, and results-oriented professional with strong leadership skills. Diana is experienced in customer relations, event logistics, market analysis, and successfully achieving targets within short, medium, and long-term timeframes.

Diana Acosta pursued their higher education at the Universidad Nacional Autónoma de México from 1992 to 1995. During this period, they completed a Licenciatura degree in Comunicación gráfica.

Links

Previous companies

Pfizer logo

Peers

View in org chart

Timeline

  • Objetivo: Sales profesional extensive in the Pharmacutical industry with an evolutionary visión of

    January, 2021 - present